Android app Apple app link

iBio Expands Pipeline with New Antibody Agreement

By Yahoo! Finance   |   2 months ago
iBio Expands Pipeline with New Antibody Agreement

iBio, Inc. partners with AstralBio to license IBIO-600, a long-acting anti-myostatin antibody for obesity and cardiometabolic disorders.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.